MTSS1 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, these data suggest that MTSS1 potentially can be targeted pharmacologically in the treatment of patients with acute myeloid leukemia and chronic myeloid leukemia, which of course could be of interest also for epithelial cancers with low MTSS1 expression.